


Troponin I

Troponin I

cobas®

REF		SYSTEM
05094810 190	100	MODULAR ANALYTICS E170 cobas e 601 cobas e 602

English

Intended use

Immunoassay for the in vitro quantitative determination of cardiac troponin I in human serum and plasma. This assay is intended to aid in the diagnosis and treatment of myocardial infarction and cardiac muscle damage.

Cardiac troponin I determinations aid in the risk stratification of patients with unstable angina pectoris or non-ST-segment elevation acute coronary syndrome with respect to relative risk of mortality, myocardial infarction, or increased probability of ischemic events requiring urgent revascularization procedures.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.

Summary

Troponin I (TnI) is a key regulatory protein of the striated musculature. Although its function in the contractile apparatus is the same in all striated muscles, TnI originating from the myocardium (cardiac TnI, molecular weight 23.9 kD) clearly differs from skeletal muscle TnI. Due to this high tissue-specificity, cardiac troponin I (cTnI) is a highly sensitive marker for myocardial damage.^{1,2,3,4,5} Cardiac TnI allows to differentiate between skeletal muscle lesions (e.g. rhabdomyolysis, polytraumatism) and myocardial injury.^{6,7,8}

In cases of acute myocardial infarction (AMI), cTnI levels in serum rise about 3-6 hours after the onset of cardiac symptoms, peak at 12-16 hours, and can remain elevated for 4-9 days.^{9,10} Elevated cTnI levels have also been reported in cases of unstable angina pectoris (UAP) and congestive heart failure (CHF).^{11,12,13,14} Cardiac TnI is a well-established prognostic marker which can predict the near-, mid- and even long-term outcome of patients with acute coronary syndrome (ACS).^{15,16,17,18}

Given that cTnI as well as cardiac troponin T are independent markers which best predict the outcome of patients with ACS, the joint committee of the European Society of Cardiology (ESC) and American College of Cardiology (ACC) redefined myocardial infarction (MI). According to this redefinition, MI is diagnosed when blood levels of cardiac troponin are above the 99th percentile of the reference limit (of a healthy population) in the clinical setting of acute ischemia. The imprecision (coefficient of variation) at the 99th percentile for troponin assays is required to be less than or equal to 10 %.^{19,20,21}

Based on the redefinition of MI several recommendations have been published concerning the role of cardiac troponin testing in patients with ACS.^{22,23,24}

In patients with UAP and those without evidence of ST segment elevation (NSTEMI) detectable levels of cardiac troponin correlate with higher incidence of mortality. Thus, the measurement of troponin can be useful in the risk stratification of these patients which is also part of the ACC/AHA (American Heart Association) guidelines for the management of patients with UAP and NSTEMI.^{25,26}

In summary, elevated troponin levels point to myocardial injury, but are not necessarily indicative of an ischemic mechanism. The term MI should be used when there is evidence of cardiac damage, as detected by marker proteins in a clinical setting consistent with myocardial ischemia. If the clinical circumstance suggests that an ischemic mechanism is unlikely, other causes of cardiac injury should be considered.²²

The Elecsys Troponin I assay employs two pairs of monoclonal antibodies specifically directed against human cardiac troponin I.

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 30 µL of sample, two biotinylated monoclonal anti-cardiac troponin I antibodies, and two monoclonal anti-cardiac troponin I antibodies labeled with a ruthenium complex^{a)} react to form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.

- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode.

a) Tris(2,2-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The reagent rackpack is labeled as TN-I.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL:
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-cardiac troponin I-Ab~biotin (gray cap), 1 bottle, 10 mL:
Two biotinylated monoclonal anti-cardiac troponin I-antibodies (mouse) 0.8 mg/L each; phosphate buffer 100 mmol/L, pH 7.4; preservative; inhibitors.
- R2 Anti-cardiac troponin I-Ab~Ru(bpy)₃²⁺ (black cap), 1 bottle, 10 mL:
Two monoclonal anti-cardiac troponin I-antibodies (mouse) labeled with ruthenium complex 0.8 mg/L and 0.005 mg/L respectively; phosphate buffer 100 mmol/L, pH 7.4; preservative; inhibitors.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	4 weeks
on the analyzers	14 days

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

K₂-EDTA, K₃-EDTA plasma and Li-heparin plasma.

Plasma (EDTA, heparin) and serum samples should not be used interchangeably.

Criterion: Slope 0.8-1.2 + coefficient of correlation ≥ 0.95.

Stable for 2 hours at 20-25 °C, 12 months at -20 °C. Freeze only once.

Troponin I

Troponin I



The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- [REF] 05094828190, Troponin I CalSet, for 4 x 1 mL
 - [REF] 05095107190, PreciControl Troponin, for 2 x 2 mL each of PreciControl Troponin 1 and 2
 - [REF] 03609987190, Diluent MultiAssay, 2 x 16 mL sample diluent
 - General laboratory equipment
 - MODULAR ANALYTICS E170, **cobas e 601** or **cobas e 602** analyzer
- Accessories for MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers:

- [REF] 04880340190, ProCell M, 2 x 2 L system buffer
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- [REF] 12102137001, AssayTip/AssayCup Combimagazine M, 48 magazines x 84 reaction vessels or pipette tips, waste bags
- [REF] 03023150001, WasteLiner, waste bags
- [REF] 03027651001, SysClean Adapter M
- [REF] 11298500316, Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

Calibration

Traceability: This method has been standardized against a commercially available troponin I assay.

Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer). Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings outside the defined limits

Quality control

For quality control, use PreciControl Troponin.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in µg/L or ng/mL).

Limitations - interference

The assay is unaffected by icterus (bilirubin < 428 µmol/L or < 25 mg/dL), hemolysis (Hb < 0.247 mmol/L or < 0.4 g/dL), lipemia (Intralipid < 1500 mg/dL) and biotin (< 123 nmol/L or < 30 ng/mL).

Falsely depressed results are obtained when using samples with higher hemoglobin concentrations.

Criterion: Recovery within ± 15 % of initial value.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of 1500 IU/mL.

There is no high-dose hook effect at troponin I concentrations up to 1000 µg/L (ng/mL).

In vitro tests were performed on 52 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to immunological components, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Limits and ranges

Measuring range

0.16-25 µg/L or ng/mL (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Blank are reported as < 0.1 µg/L or ng/mL. Values above the Limit of Blank but below the Limit of Detection will not be flagged by the instrument. Values above the measuring range are reported as > 25 µg/L or ng/mL (or up to 250 µg/L or ng/mL for 10-fold diluted samples).

Lower limits of measurement

Limit of Blank (LoB), Limit of Detection (LoD) and Limit of Quantitation (LoQ)

Limit of Blank = 0.1 µg/L (ng/mL)

Limit of Detection = 0.16 µg/L (ng/mL)

Limit of Quantitation = 0.3 µg/L (ng/mL)

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A requirements.

The Limit of Quantitation was determined using the result of functional sensitivity testing.

The Limit of Blank is the 95th percentile value from n ≥ 60 measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

Troponin I

Troponin I



The Limit of Quantitation (functional sensitivity) is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of $\leq 10\%$.

Dilution

Samples with troponin I concentrations above the measuring range can be diluted with Diluent MultiAssay. The recommended dilution is 1:10 (either automatically by the MODULAR ANALYTICS E170, **cobas e 601** or **cobas e 602** analyzers or manually). The concentration of the diluted sample must be $> 3 \mu\text{g/L}$ (ng/mL).

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzers, the MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** software automatically takes the dilution into account when calculating the sample concentration.

Expected values

In studies performed with the Elecsys Troponin I assay involving 839 healthy volunteers in 4 US sites and 2 EU sites, the upper reference limit (99th percentile) for cTnI was $0.16 \mu\text{g/L}$ (ng/mL) (95 % confidence interval 0.12-0.60).

The lowest concentration with a CV less than or equal to 10 % with the Elecsys Troponin I assay was $0.30 \mu\text{g/L}$ (ng/mL).

Due to the release kinetics of cTnI, a result below the decision limit within the first hours of the onset of symptoms does not rule out myocardial infarction with certainty. If myocardial infarction is still suspected, repeat the test at appropriate intervals.

Factors associated with elevated values

Published clinical studies have shown elevations of cTnI in patients with myocardial injury, as seen in unstable angina pectoris, cardiac contusions, and heart transplants.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol (EP5-A2) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplication each for 21 days ($n = 84$). The following results were obtained:

Sample	Mean $\mu\text{g/L}$ (ng/mL)	Repeatability		Intermediate precision	
		SD $\mu\text{g/L}$ (ng/mL)	CV %	SD $\mu\text{g/L}$ (ng/mL)	CV %
Human serum 1	0.180	0.026	14.2	0.029	15.9
Human serum 2	0.197	0.020	10.0	0.026	13.4
Human serum 3	0.322	0.017	5.3	0.028	8.7
Human serum 4	0.425	0.022	5.2	0.031	7.3
Human serum 5	17.6	0.479	2.7	0.823	4.7
PreciControl Tn1	0.340	0.024	7.0	0.027	8.0
PreciControl Tn2	18.0	0.475	2.6	0.783	4.4

Method comparison

A comparison of the Elecsys Troponin I assay (MODULAR ANALYTICS E170 analyzer; y) and the Elecsys Troponin I STAT assay (Elecsys 2010 analyzer; x) using clinical samples gave the following correlations ($\mu\text{g/L}$ or ng/mL):

Number of samples measured: 121

Passing/Bablok²⁷ Linear regression
 $y = 0.973x - 0.002$ $y = 0.993x - 0.055$
 $r = 0.965$ $r = 0.994$

The sample concentrations were between approximately 0.165 and $24.6 \mu\text{g/L}$ (ng/mL).

Analytical specificity

The Elecsys Troponin I assay does not show any significant cross-reaction with the following substances (tested with troponin I concentrations of approximately 0.4 ng/mL and 3 ng/mL):

h-skeletal muscle troponin I 0.03 %, h-cardiac troponin T 0.05 %, h-skeletal muscle troponin T 0.0 % (not detectable) and human troponin C 0.0 % (not detectable).

Diagnostic sensitivity and specificity

One clinical center in Europe and one center in the US participated in prospective studies with patients presenting with chest pain in the emergency department. 358 patients were ruled in for calculation of sensitivity and specificity as selected by the following criteria: Onset of chest pain within 24 hours before admission, chest pain for > 20 minutes, assessment by ECG criteria, age > 20 years, no pregnancy, no previous MI within 3 weeks before admission and a minimum of two blood draws. Another criteria was the availability of a test result with a commercially available cardiac troponin I test measured in parallel. Patients with non-vascular cardiac disease were excluded from the calculations. The patients were diagnosed according to the current guideline for the assessment of acute myocardial infarction with inclusion of results by the routine troponin tests.^{15,16} 69 patients were diagnosed as STEMI or NSTEMI, 80 patients as unstable angina pectoris, and 209 patients had developed chest pain that was not caused by cardiac injury. A Receiver Operating Characteristic (ROC) curve was calculated from the peak troponin values. The ROC curve had an area under the curve (AUC) of 0.96 (95 % confidence interval 0.91-0.98). The optimal cut-off in the assessment of acute myocardial infarction was calculated by ROC analysis at $0.30 \mu\text{g/L}$ (ng/mL) from peak troponin I values. Sensitivity and specificity were calculated for the ROC optimized cut-off ($0.30 \mu\text{g/L}$ (ng/mL)) in the table below.

Cut-off $\mu\text{g/L}$ (ng/mL)	Sensitivity %	N	95 % CI ^{b)} (%)	Specificity %	N	95 % CI (%)
0.30	84	58/69	74-91	94	272/289	91-96

b) CI = confidence interval

Calculation of the peak values of the commercially available cardiac troponin I test measured in parallel yielded the following results for the ROC optimized cut-off of $0.50 \mu\text{g/L}$ (ng/mL).

Cut-off $\mu\text{g/L}$ (ng/mL)	Sensitivity %	N	95 % CI (%)	Specificity %	N	95 % CI (%)
0.50	61	42/69	49-72	100	289/289	99-100

The sensitivity and specificity was in addition calculated for different time intervals from admission to the hospital (Elecsys Troponin I test):

Time periods from admission (hours)	Cut-off $\mu\text{g/L}$ (ng/mL)	Sensitivity %	N	95 % confidence interval (%)
0	0.30	69	46/67	57-79
0-3	0.30	81	51/63	70-89
3-6	0.30	79	30/38	64-89
> 6	0.30	69	20/29	51-83

Time periods from admission (hours)	Cut-off $\mu\text{g/L}$ (ng/mL)	Specificity %	N	95 % confidence interval (%)
0	0.30	99	276/280	96-99
0-3	0.30	96	269/280	93-98
3-6	0.30	96	197/205	93-98
> 6	0.30	97	133/137	93-99

Troponin I

Troponin I



Note: In the event that an initial troponin value presents as negative and the subject presents clinical AMI signs and symptoms, a second sample should be taken after 6 hours and a follow-up measurement should be performed.

References

- Perry SV. The regulation of contractile activity in muscle. *Biochem Soc Trans* 1979;7:593-617.
- Wilkinson JM, Grand RJA. Comparison of amino acid sequence of troponin I from different striated muscles. *Nature* 1978;271:31-35.
- Wade R, Eddy R, Shows TB, et al. cDNA sequence, tissue-specific expression and chromosomal mapping of the human slow-twitch skeletal muscle isoform of troponin I. *Genomics* 1990;7:346-357.
- Cummins P, Perry V. Troponin I from human skeletal and cardiac muscles. *Biochem J* 1978;171:251-259.
- Vallins JW, Brand NJ, Dabhaden N, et al. Molecular cloning of human cardiac troponin I using polymerase chain reaction. *FEBS Lett* 1990;270:57-61.
- Larue C, Calzolari C, Bertinchant JP, et al. Cardiac-specific immunoassay of troponin I in the early phase of acute myocardial infarction. *Clin Chem* 1993;39(6):972-979.
- Bakker AJ, Koelmay MJW, Gorgels JPMC, et al. Failure of new biochemical markers to exclude acute myocardial infarction at admission. *Lancet* 1993;342:1220-1222.
- Mair J, Wagner I, Puschendorf B, et al. Cardiac troponin I to diagnose myocardial injury (letter). *Lancet* 1993;341:838-839.
- Mair J, Morandell D, Genser N, et al. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. *Clin Chem* 1995;41:1266-1272.
- Mair J, Genser N, Morandell D, et al. Cardiac troponin I in the diagnosis of myocardial injury and infarction. *Clinica Chimica Acta* 1996;245:19-38.
- Galvani M, Ottani F, Ferrini D, et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. *Circulation* 1997;95:2053-2059.
- Missov ED, De Marco T. Clinical insights on the use of highly sensitive cardiac troponin assays. *Clin Chem Acta* 1999;284:175-185.
- Heidenreich PA, Go A, Melsop KA, et al. Prediction of risk for patients with unstable angina. *AHRQ Publication No.01-E001 December, 2000; No. 31.*
- Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. *Circulation* 2000;102:149-156.
- Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. *N Engl J Med* 1996;335:1342-1349.
- Tanasijevic MJ, Cannon CP, Antman EM. The role of cardiac troponin I (cTnI) in risk stratification of patients with unstable coronary artery disease. *Clin Cardiol* 1999;22:13-16.
- Morrow DA, Rifai N, Tanasijevic MJ, et al. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: A thrombolysis in myocardial infarction (TIMI) IIB substudy. *Clin Chem* 2000;46(4):453-460.
- Antman EM, Fox KM. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: Proposed revisions. *Am Heart J* 2000;139:461-475.
- Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *JACC* 2000;36(3):959-969.
- The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial Infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *Eur Heart J* 2000;21:1502-1513.
- Thygesen K, Alpert JS, White HD on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: universal definition of myocardial infarction. *Eur Heart J* 2007;28:2525-2538.
- Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. *Circulation* 2000;102:1216-1220.
- Apple FS, Wu AHB. Myocardial infarction redefined: role of cardiac troponin testing. *Clin Chem* 2001;47:377-379.
- Jaffe AS. The clinical impact of the universal diagnosis of myocardial infarction. *Clin Chem Lab Med* 2008;46:1485-1488.
- Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive Summary and Recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). *Circulation* 2000;102(10):1193-1209.
- Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive Summary and Recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). *Circulation* 2002.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume after reconstitution or mixing

COBAS, COBAS E, ELECSYS, MODULAR and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Significant additions or changes are indicated by a change bar in the margin.

© 2014, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

